RBC Capital Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $195.00. The company’s shares closed yesterday at $173.83.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Timashev is a 5-star analyst with an average return of 20.7% and a 58.55% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Exelixis, Cytokinetics, and Axsome Therapeutics.

In addition to RBC Capital, Jazz Pharmaceuticals also received a Buy from Piper Sandler’s David Amsellem in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ).

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.13 billion and a net profit of $251.41 million. In comparison, last year the company earned a revenue of $1.05 billion and had a net profit of $215.06 million

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Most recently, in December 2025, Mary Elizabeth Henderson, the SVP Tech. Op of JAZZ sold 2,238.00 shares for a total of $379,363.38.